New drugs for non‐alcoholic steatohepatitis
Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in Western countries. At present the safest and most effective first‐line therapy for the management of non‐alcoholic steatohepatitis (NASH) is lifestyle modification with diet and exercise. However, long‐term ad...
Gespeichert in:
| Veröffentlicht in: | Liver international 2020-02, Vol.40 (S1), p.96-101 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 101 |
|---|---|
| container_issue | S1 |
| container_start_page | 96 |
| container_title | Liver international |
| container_volume | 40 |
| creator | Cardoso, Ana‐Carolina Figueiredo‐Mendes, Claudio A. Villela‐Nogueira, Cristiane Sanyal, Arun J. |
| description | Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in Western countries. At present the safest and most effective first‐line therapy for the management of non‐alcoholic steatohepatitis (NASH) is lifestyle modification with diet and exercise. However, long‐term adherence to lifestyle modification is rare in the target population, leading to progression of liver disease and its complications such as cirrhosis and hepatocellular carcinoma. Thus, new drugs that focus mainly on the pathogenesis of NASH to target inflammation and fibrogenesis are under investigation. This mini‐review summarizes the results of pivotal finalized phase 2 studies, and provide an outline of ongoing phase 2 and phase 3 studies. |
| doi_str_mv | 10.1111/liv.14354 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_wiley</sourceid><recordid>TN_cdi_proquest_miscellaneous_2359393388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2359393388</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4194-d24961651560dd20ff4b8e2394fa8e987998b13a86c4f6ebeaf7955877c453923</originalsourceid><addsrcrecordid>eNqN0MtKAzEUBuAgitbqwheQghtFpuY6kyyleIOiG3U7ZDInGplO6mTG0p2P4DP6JKa2diEIZpOz-M7h50fogOAhie-scm9DwpngG6hHeCYTRhnZXM-U7aDdEF4wJkoJso12GMVZlhLRQ8ktzAZl0z2FgfXNoPb15_uHrox_9pUzg9CCbv0zTHXrWhf20JbVVYD91d9HD5cX96PrZHx3dTM6HyeGE8WTknKVklQQkeKypNhaXkigTHGrJSiZKSULwrRMDbcpFKBtpoSQWWa4YIqyPjpe3p02_rWD0OYTFwxUla7BdyGnTCimGJMy0qNf9MV3TR3TLZRkRJIo--hkqUzjQ2jA5tPGTXQzzwnOFx3mscP8u8NoD1cXu2IC5Vr-lBbB6RLMoPA2GAe1gTXDGAuqVMrigL-1_L8euTY27euR7-o2rp6tVl0F878j5-Obx2X2L6AEmhE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2358318139</pqid></control><display><type>article</type><title>New drugs for non‐alcoholic steatohepatitis</title><source>Access via Wiley Online Library</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Cardoso, Ana‐Carolina ; Figueiredo‐Mendes, Claudio ; A. Villela‐Nogueira, Cristiane ; Sanyal, Arun J.</creator><creatorcontrib>Cardoso, Ana‐Carolina ; Figueiredo‐Mendes, Claudio ; A. Villela‐Nogueira, Cristiane ; Sanyal, Arun J.</creatorcontrib><description>Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in Western countries. At present the safest and most effective first‐line therapy for the management of non‐alcoholic steatohepatitis (NASH) is lifestyle modification with diet and exercise. However, long‐term adherence to lifestyle modification is rare in the target population, leading to progression of liver disease and its complications such as cirrhosis and hepatocellular carcinoma. Thus, new drugs that focus mainly on the pathogenesis of NASH to target inflammation and fibrogenesis are under investigation. This mini‐review summarizes the results of pivotal finalized phase 2 studies, and provide an outline of ongoing phase 2 and phase 3 studies.</description><identifier>ISSN: 1478-3223</identifier><identifier>EISSN: 1478-3231</identifier><identifier>DOI: 10.1111/liv.14354</identifier><identifier>PMID: 32077615</identifier><language>eng</language><publisher>HOBOKEN: Wiley</publisher><subject>Cirrhosis ; Complications ; Drugs ; Fatty liver ; Gastroenterology & Hepatology ; Hepatocellular carcinoma ; Life Sciences & Biomedicine ; Liver ; Liver cirrhosis ; Liver diseases ; Pathogenesis ; Science & Technology</subject><ispartof>Liver international, 2020-02, Vol.40 (S1), p.96-101</ispartof><rights>2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd</rights><rights>2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><rights>2020 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>23</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000529963000015</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c4194-d24961651560dd20ff4b8e2394fa8e987998b13a86c4f6ebeaf7955877c453923</citedby><cites>FETCH-LOGICAL-c4194-d24961651560dd20ff4b8e2394fa8e987998b13a86c4f6ebeaf7955877c453923</cites><orcidid>0000-0003-1355-2368 ; 0000-0001-8682-5748 ; 0000-0002-4552-8453 ; 0000-0001-8668-4236</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fliv.14354$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fliv.14354$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,28253,45579,45580</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32077615$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cardoso, Ana‐Carolina</creatorcontrib><creatorcontrib>Figueiredo‐Mendes, Claudio</creatorcontrib><creatorcontrib>A. Villela‐Nogueira, Cristiane</creatorcontrib><creatorcontrib>Sanyal, Arun J.</creatorcontrib><title>New drugs for non‐alcoholic steatohepatitis</title><title>Liver international</title><addtitle>LIVER INT</addtitle><addtitle>Liver Int</addtitle><description>Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in Western countries. At present the safest and most effective first‐line therapy for the management of non‐alcoholic steatohepatitis (NASH) is lifestyle modification with diet and exercise. However, long‐term adherence to lifestyle modification is rare in the target population, leading to progression of liver disease and its complications such as cirrhosis and hepatocellular carcinoma. Thus, new drugs that focus mainly on the pathogenesis of NASH to target inflammation and fibrogenesis are under investigation. This mini‐review summarizes the results of pivotal finalized phase 2 studies, and provide an outline of ongoing phase 2 and phase 3 studies.</description><subject>Cirrhosis</subject><subject>Complications</subject><subject>Drugs</subject><subject>Fatty liver</subject><subject>Gastroenterology & Hepatology</subject><subject>Hepatocellular carcinoma</subject><subject>Life Sciences & Biomedicine</subject><subject>Liver</subject><subject>Liver cirrhosis</subject><subject>Liver diseases</subject><subject>Pathogenesis</subject><subject>Science & Technology</subject><issn>1478-3223</issn><issn>1478-3231</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><recordid>eNqN0MtKAzEUBuAgitbqwheQghtFpuY6kyyleIOiG3U7ZDInGplO6mTG0p2P4DP6JKa2diEIZpOz-M7h50fogOAhie-scm9DwpngG6hHeCYTRhnZXM-U7aDdEF4wJkoJso12GMVZlhLRQ8ktzAZl0z2FgfXNoPb15_uHrox_9pUzg9CCbv0zTHXrWhf20JbVVYD91d9HD5cX96PrZHx3dTM6HyeGE8WTknKVklQQkeKypNhaXkigTHGrJSiZKSULwrRMDbcpFKBtpoSQWWa4YIqyPjpe3p02_rWD0OYTFwxUla7BdyGnTCimGJMy0qNf9MV3TR3TLZRkRJIo--hkqUzjQ2jA5tPGTXQzzwnOFx3mscP8u8NoD1cXu2IC5Vr-lBbB6RLMoPA2GAe1gTXDGAuqVMrigL-1_L8euTY27euR7-o2rp6tVl0F878j5-Obx2X2L6AEmhE</recordid><startdate>202002</startdate><enddate>202002</enddate><creator>Cardoso, Ana‐Carolina</creator><creator>Figueiredo‐Mendes, Claudio</creator><creator>A. Villela‐Nogueira, Cristiane</creator><creator>Sanyal, Arun J.</creator><general>Wiley</general><general>Wiley Subscription Services, Inc</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1355-2368</orcidid><orcidid>https://orcid.org/0000-0001-8682-5748</orcidid><orcidid>https://orcid.org/0000-0002-4552-8453</orcidid><orcidid>https://orcid.org/0000-0001-8668-4236</orcidid></search><sort><creationdate>202002</creationdate><title>New drugs for non‐alcoholic steatohepatitis</title><author>Cardoso, Ana‐Carolina ; Figueiredo‐Mendes, Claudio ; A. Villela‐Nogueira, Cristiane ; Sanyal, Arun J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4194-d24961651560dd20ff4b8e2394fa8e987998b13a86c4f6ebeaf7955877c453923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Cirrhosis</topic><topic>Complications</topic><topic>Drugs</topic><topic>Fatty liver</topic><topic>Gastroenterology & Hepatology</topic><topic>Hepatocellular carcinoma</topic><topic>Life Sciences & Biomedicine</topic><topic>Liver</topic><topic>Liver cirrhosis</topic><topic>Liver diseases</topic><topic>Pathogenesis</topic><topic>Science & Technology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cardoso, Ana‐Carolina</creatorcontrib><creatorcontrib>Figueiredo‐Mendes, Claudio</creatorcontrib><creatorcontrib>A. Villela‐Nogueira, Cristiane</creatorcontrib><creatorcontrib>Sanyal, Arun J.</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Liver international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cardoso, Ana‐Carolina</au><au>Figueiredo‐Mendes, Claudio</au><au>A. Villela‐Nogueira, Cristiane</au><au>Sanyal, Arun J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New drugs for non‐alcoholic steatohepatitis</atitle><jtitle>Liver international</jtitle><stitle>LIVER INT</stitle><addtitle>Liver Int</addtitle><date>2020-02</date><risdate>2020</risdate><volume>40</volume><issue>S1</issue><spage>96</spage><epage>101</epage><pages>96-101</pages><issn>1478-3223</issn><eissn>1478-3231</eissn><abstract>Non‐alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease in Western countries. At present the safest and most effective first‐line therapy for the management of non‐alcoholic steatohepatitis (NASH) is lifestyle modification with diet and exercise. However, long‐term adherence to lifestyle modification is rare in the target population, leading to progression of liver disease and its complications such as cirrhosis and hepatocellular carcinoma. Thus, new drugs that focus mainly on the pathogenesis of NASH to target inflammation and fibrogenesis are under investigation. This mini‐review summarizes the results of pivotal finalized phase 2 studies, and provide an outline of ongoing phase 2 and phase 3 studies.</abstract><cop>HOBOKEN</cop><pub>Wiley</pub><pmid>32077615</pmid><doi>10.1111/liv.14354</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-1355-2368</orcidid><orcidid>https://orcid.org/0000-0001-8682-5748</orcidid><orcidid>https://orcid.org/0000-0002-4552-8453</orcidid><orcidid>https://orcid.org/0000-0001-8668-4236</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1478-3223 |
| ispartof | Liver international, 2020-02, Vol.40 (S1), p.96-101 |
| issn | 1478-3223 1478-3231 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2359393388 |
| source | Access via Wiley Online Library; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Cirrhosis Complications Drugs Fatty liver Gastroenterology & Hepatology Hepatocellular carcinoma Life Sciences & Biomedicine Liver Liver cirrhosis Liver diseases Pathogenesis Science & Technology |
| title | New drugs for non‐alcoholic steatohepatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-12T15%3A26%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_wiley&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20drugs%20for%20non%E2%80%90alcoholic%20steatohepatitis&rft.jtitle=Liver%20international&rft.au=Cardoso,%20Ana%E2%80%90Carolina&rft.date=2020-02&rft.volume=40&rft.issue=S1&rft.spage=96&rft.epage=101&rft.pages=96-101&rft.issn=1478-3223&rft.eissn=1478-3231&rft_id=info:doi/10.1111/liv.14354&rft_dat=%3Cproquest_wiley%3E2359393388%3C/proquest_wiley%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2358318139&rft_id=info:pmid/32077615&rfr_iscdi=true |